Idarucizumab: What Should We Know?

E-ISSN： 1873-5592|19|1|81-88

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.1, 2018-01, pp. : 81-88

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Breaking the Barrier in Stroke: What Should we Know? A Mini-Review

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3615-3623

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropsychiatric Adverse Effects of Mefloquine: What Do We Know and What Should We Do?

By Nosten F.

CNS Drugs, Vol. 11, Iss. 1, 1999-01 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite

Dilemmas about the toxicological consequences of metal-on-metal hip prostheses - What we do and do not know, and what we should do?

By Brent Jeffrey

Clinical Toxicology, Vol. 51, Iss. 4, 2013-05 ,pp. : 195-198

Informa Healthcare

Access to resources Recommend Favorite

Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know

By Jones Drew R Miller Grover P

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 7, 2011-07 ,pp. : 857-874

Informa Healthcare

Access to resources Recommend Favorite

Adenosine Receptors: What We Know and What We are Learning

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 9, 2010-06 ,pp. : 860-877

Bentham Science Publishers

Access to resources Recommend Favorite